{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:46Z","timestamp":1783577746488,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    Duchenne muscular dystrophy (DMD) is an X-linked disorder characterized by progressive muscle weakness. Here we provide a case report for a male aged 7 years and 3 months diagnosed with DMD after detecting a deletion of exons 48\u201350 of the\n                    <jats:italic>DMD<\/jats:italic>\n                    gene. The child initially presented with elevated transaminases during a febrile illness at 17 months. Further evaluation revealed significantly increased creatine phosphokinase and troponin levels. He exhibited delayed gross motor milestones and developed left ventricular diastolic dysfunction. At 24 months of age, weekly intravenous eteplirsen therapy was initiated, along with enalapril to manage cardiac symptoms. Over 5 years, the patient demonstrated stable cardiac function and gradual motor improvement. Despite persistent hyperlordosis and waddling gait, his 6-minute walk test remained stable. To our knowledge, this is the first documented case of DMD reporting cardiac outcomes after eteplirsen treatment in a patient as young as 24 months of age.\n                  <\/jats:p>","DOI":"10.3389\/fped.2026.1672692","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:56Z","timestamp":1783575356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: The effect of early initiation of eteplirsen treatment on the cardiac and motor disease course in an individual with Duchenne muscular dystrophy"],"prefix":"10.3389","volume":"14","author":[{"given":"Yamen","family":"Masalha","sequence":"first","affiliation":[{"name":"Pediatric Department B, Emek Medical Center","place":["Afula, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Zehavi","sequence":"additional","affiliation":[{"name":"Pediatric Department B, Emek Medical Center","place":["Afula, Israel"]},{"name":"Rappaport School of Medicine, Technion","place":["Haifa, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banan","family":"Musallam","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Unit, Emek Medical Center","place":["Afula, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Khamaysi","sequence":"additional","affiliation":[{"name":"Pediatric Department B, Emek Medical Center","place":["Afula, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maali","family":"Abu Omer","sequence":"additional","affiliation":[{"name":"Pediatric Cardiology Unit, Emek Medical Center","place":["Afula, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Fink","sequence":"additional","affiliation":[{"name":"Pediatric Cardiology Unit, Emek Medical Center","place":["Afula, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Pediatric Department B, Emek Medical Center","place":["Afula, Israel"]},{"name":"Rappaport School of Medicine, Technion","place":["Haifa, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: gene therapy for Duchenne muscular dystrophy","volume":"20","author":"Asher","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e230086","DOI":"10.57264\/cer-2023-0086","article-title":"Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA","volume":"12","author":"Iff","year":"2023","journal-title":"J Comp Eff Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacbts.2021.11.004","article-title":"Cardiovascular disease in Duchenne muscular dystrophy: overview and insight into novel therapeutic targets","volume":"7","author":"Schultz","year":"2022","journal-title":"JACC Basic to Translational Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","article-title":"Contemporary cardiac issues in Duchenne muscular dystrophy","volume":"131","author":"McNally","year":"2015","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"00176","DOI":"10.1183\/23120541.00176-2023","article-title":"Cardiomyopathy as cause of death in duchenne muscular dystrophy: a longitudinal observational study","volume":"9","author":"Lechner","year":"2023","journal-title":"ERJ Open Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamacardio.2016.4910","article-title":"Cardiomyopathy in muscular dystrophy: when to treat?","volume":"2","author":"McNally","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"175675","DOI":"10.1016\/j.ejphar.2023.175675","article-title":"Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach","volume":"947","author":"Patterson","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/circulationaha.117.028382","article-title":"Mutation-based therapy for Duchenne muscular dystrophy: antisense treatment arrives in the clinic","volume":"136","author":"McNally","year":"2017","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/jnd-210643","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping","volume":"8","author":"McDonald","year":"2021","journal-title":"PROMOVI Trial. J Neuromuscul Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"key":"B15","volume-title":"Enalapril. ed. StatPearls.","author":"Faruqi","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.nmd.2023.03.008","article-title":"Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6\u221248 months with Duchenne muscular dystrophy amenable to exon 51 skipping","volume":"33","author":"Mercuri","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"B17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4330\/wjc.v7.i7.410","article-title":"Cardiac involvement in Duchenne and Becker muscular dystrophy","volume":"7","author":"Mavrogeni","year":"2015","journal-title":"World J Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12872-022-02688-5","article-title":"Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging","volume":"22","author":"Batra","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10554-008-9370-9","article-title":"Duchenne muscular dystrophy; a cardiomyopathy that can be prevented?","volume":"25","author":"Mulder","year":"2009","journal-title":"Int J Cardiovasc Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-g","article-title":"The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy","volume":"26","author":"Nigro","year":"1990","journal-title":"Int J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/children7110249","article-title":"Is it possible for children in Duchenne muscular dystrophy to preserve cardiac function with medical assistance?","volume":"7","author":"Kim","year":"2020","journal-title":"Children (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3390\/jcm9103186","article-title":"Duchenne dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies","volume":"9","author":"Adorisio","year":"2020","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","article-title":"Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future","volume":"72","author":"\u0141oboda","year":"2020","journal-title":"Pharmacol Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.21037\/jtd-22-1528","article-title":"Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study","volume":"15","author":"Kisel","year":"2023","journal-title":"J Thorac Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2012.02.064","article-title":"Effects of angiotensin-converting enzyme inhibitors and\/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy","volume":"110","author":"Viollet","year":"2012","journal-title":"Am J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.omtm.2023.07.004","article-title":"Prevention of early-onset cardiomyopathy in Dmd exon 52\u221254 deletion mice by CRISPR-Cas9-mediated exon skipping","volume":"30","author":"Rok","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/22143602251366721","article-title":"Association between exon-skipping therapy with eteplirsen and cardiac outcomes in Duchenne muscular dystrophy","volume":"13","author":"Iff","year":"2026","journal-title":"J Neuromuscul Dis"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1672692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:57Z","timestamp":1783575357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1672692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":27,"alternative-id":["10.3389\/fped.2026.1672692"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1672692","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1672692"}}